Parnell Pharmaceuticals Holdings Ltd. (PARNF)
Stock Price:
$0.140 USD
-0.010 (-6.67%)
Updated Aug 5, 2020 4:00 PM EDT - End of day
Key Info
| Market Cap |
2.54M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
n/a |
| Shares Out |
18.15M |
| EPS (ttm) |
-1.05 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 5, 2020 |
| Last Price |
$0.140 |
| Previous Close |
$0.150 |
| Change ($) |
-0.010 |
| Change (%) |
-6.67% |
| Day's Open |
0.140 |
| Day's Range |
0.140 - 0.140 |
| Day's Volume |
1,000 |
| 52-Week Range |
0.040 - 0.360 |
More Stats
| Market Cap |
2.54M |
| Enterprise Value |
n/a |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
18.15M |
| Float |
n/a |
| EPS (basic) |
n/a |
| EPS (diluted) |
-1.05 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
27,414 |
| Short Ratio |
0.29 |
| Short % of Float |
0.42% |
| Beta |
2.61 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
n/a |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
n/a |
| Net Cash / Share |
n/a |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
4.11% |
| ROE |
n/a |
| ROIC |
n/a |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
11.2
Current: $0.140
High
11.2
Target: 11.24
*Average 12-month USD price target from 1 stock analysts.
Financial Overview
No financial data available for this stock yet.
Company Details
| Full Name |
Parnell Pharmaceuticals Holdings Ltd. |
| CEO |
Brad R. McCarthy |
Stock Information
| Ticker Symbol |
PARNF |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
OTCMKTS: PARNF |
| IPO Date |
June 18, 2014 |
Description
Parnell Pharmaceuticals Holdings Ltd, a veterinary pharmaceutical company, focuses on developing, manufacturing, and commercializing various animal health solutions. The company operates through four segments: Companion Animal, Production Animal - U.S., Production Animal - Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproductive hormone products for improving cattle breeding performance; Zydax for the treatment of osteoarthritis (OA) in dogs and horses; and Glyde, a nutraceutical product aids in the treatment of OA, as well as Parnell PROcept, which adds an additional injection of estroPLAN after the first injection. The company also operates mySYNCH, a digital tool to help veterinarians and producers optimize reproduction and maximize economic gains. Parnell Pharmaceuticals Holdings Ltd was incorporated in 2009 and is headquartered in Alexandria, Australia.